Mercury Laboratories Complete Financial Statements
In FY2026, Mercury Laboratories (MERCURYLAB) reported revenue ₹76 Cr, net profit ₹5 Cr and EPS ₹40.28, with a net profit margin of 6.6% and ROE of 8.6%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore MERCURYLAB investment value to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
MERCURYLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
MERCURYLAB YoY (March 2025 vs March 2026), net profit +66.7%, EBITDA +12.5%, expenses -1.5%. Review MERCURYLAB earnings multiple to evaluate earnings-based valuation against sector peers.
MERCURYLAB Income Statement — Revenue, EBITDA & Net Profit
Mercury Laboratories revenue ₹76 Cr, EBITDA ₹9 Cr, net profit ₹5 Cr, EPS ₹40.28 (2026) — net profit margin 6.6%. For live price, earnings ratios and company overview, see Mercury Laboratories stock price NSE.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76 | 76 | 77 | 77 | 59 | 70 | 58 | 57 | 52 | 48 | 48 | 42 |
| Expenses | 67 | 68 | 67 | 67 | 51 | 59 | 51 | 50 | 48 | 41 | 41 | 35 |
| EBITDA | 9 | 8 | 10 | 10 | 8 | 11 | 7 | 7 | 5 | 7 | 7 | 7 |
| Operating Profit Margin % | 11.00% | 9.00% | 12.00% | 11.00% | 12.00% | 14.00% | 11.00% | 10.00% | 9.00% | 14.00% | 14.00% | 14.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 7 | 5 | 7 | 7 | 5 | 8 | 4 | 4 | 3 | 5 | 5 | 5 |
| Tax | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 1 | 1 |
| Net Profit | 5 | 3 | 6 | 6 | 4 | 5 | 3 | 3 | 2 | 3 | 4 | 3 |
| Earnings Per Share (₹) | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 | 16.78 | 22.53 | 32.69 | 27.61 |
MERCURYLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
MERCURYLAB total assets ₹79 Cr, total equity ₹58 Cr, total liabilities ₹ Cr (2026) — ROE 8.6%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 79 | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 | 47 | 43 |
| Current Assets | 45 | 40 | 40 | 40 | 35 | 38 | 32 | 32 | 30 | 32 | 28 | 23 |
| Fixed Assets | 34 | 25 | 24 | 24 | 26 | 26 | 24 | 24 | 21 | 18 | 19 | 20 |
| Capital Work in Progress | 10 | 9 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 40 | 40 | 40 | 37 | 39 | 33 | 33 | 31 | 32 | 28 | 23 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 9 | 6 | 5 | 4 | 6 | 10 | 9 | 11 | 12 | 10 | 4 | 4 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 58 | 54 | 51 | 46 | 40 | 37 | 32 | 29 | 26 | 25 | 22 | 18 |
| Share Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves & Surplus | 57 | 52 | 50 | 44 | 39 | 36 | 31 | 28 | 25 | 23 | 21 | 17 |
MERCURYLAB Cash Flow Statement — Operating, Investing & Financing
Mercury Laboratories operating cash flow ₹4 Cr, investing ₹-9 Cr, financing ₹-1 Cr, net cash flow ₹-6 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 4 | 8 | 3 | 5 | 8 | 6 | 5 | 5 | 2 | 0 | 4 |
| Investing Activities | -9 | -6 | -1 | -2 | -5 | -1 | -5 | -4 | -2 | 0 | -2 |
| Financing Activities | -1 | -1 | -1 | -1 | -1 | -3 | -3 | 1 | 0 | 1 | -2 |
| Net Cash Flow | -6 | 1 | 0 | 2 | 2 | 1 | -2 | 2 | 0 | 0 | 0 |